P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia

Shen Li; Bin Yu; Dongmei Wang; Luyao Xia; Li Wang; Dachun Chen; Meihong Xiu; Xiang Yang Zhang

doi:10.1016/j.jad.2022.12.143

P50 sensory gating, cognitive deficits and depressive symptoms in first-episode antipsychotics-naïve schizophrenia

J Affect Disord. 2023 Mar 1:324:153-161. doi: 10.1016/j.jad.2022.12.143. Epub 2022 Dec 29.

Authors

Shen Li¹, Bin Yu², Dongmei Wang³, Luyao Xia³, Li Wang³, Dachun Chen⁴, Meihong Xiu⁴, Xiang Yang Zhang⁵

Affiliations

¹ Institute of Mental Health, Tianjin Anding Hospital, Mental health center of Tianjin Medical University, Tianjin, China.
² Institute of Applied Psychology, Tianjin University, Tianjin, China; Academy of Medical Engineering and Translational Medicine, Tianjin University, China.
³ CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; Department of Psychology, University of Chinese Academy of Sciences, Beijing, China.
⁴ Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, China.
⁵ CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; Department of Psychology, University of Chinese Academy of Sciences, Beijing, China. Electronic address: zhangxy@psych.ac.cn.

PMID: 36587903
DOI: 10.1016/j.jad.2022.12.143

Abstract

Objective: Sensory gating P50 (SG-P50) may be involved in the pathophysiological mechanisms of impaired cognition in schizophrenia (SCZ). Comorbid depressive symptoms are common in SCZ patients and are also found to be associated with their cognitive impairment. However, it is unclear whether SG-P50 is abnormal in first episode antipsychotics naïve (FEAN) SCZ patients with depressive symptoms. Our aimed to investigate the relationships between SG-P50, depressive symptoms and neurocognition in FEAN-SCZ patients.

Methods: We recruited 103 FEAN-SCZ patients (depression: n = 63; non-depression: n = 40) and 55 healthy controls. SG-P50 was measured using the standard auditory dual-click (S1&S2) paradigm. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Depression Rating Scale-17 (HDRS-17). Cognitive performance was evaluated using the MATRICS Consensus Cognitive Battery (MCCB).

Results: Compared with non-depressive patients, depressive patients had a significantly larger S2 amplitude (p = 0.005) and a higher S2/S1 ratio at trend level (p = 0.075) after corrected. There were significant differences in the scores of CPT-IP and Mazes (NAB) between depressive and non-depressive FEAN-SCZ patients (both p values < 0.05). For all patients, the SG-P50 S2/S1 ratio was significantly correlated with HDRS-17 score (r = 0.23, p = 0.020) and MCCB-Symbol coding (r = -0.16, p = 0.043). For depressive FEAN-SCZ patients, S2 amplitude was an independent predictor of the MCCB-Mazes (NAB) (β = -0.31, t = -2.52, p = 0.015).

Conclusions: SG-P50 deficit may be an informational biomarker for depressive symptoms and neurocognitive impairments in FEAN-SCZ patients.

Keywords: Cognition; Depressive symptoms; First episode; P50 sensory gating; Schizophrenia.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antipsychotic Agents* / pharmacology
Antipsychotic Agents* / therapeutic use
Cognition
Cognitive Dysfunction* / etiology
Depression
Electroencephalography
Evoked Potentials, Auditory / physiology
Humans
Schizophrenia* / complications
Schizophrenia* / drug therapy
Sensory Gating / physiology

Substances

Antipsychotic Agents